

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Hong Kong Life Sciences and Technologies Group Limited**

**香港生命科學技術集團有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 8085)**

**ANNOUNCEMENT IN RELATION TO THE NOTICE OF  
ANNUAL GENERAL MEETING AND CIRCULAR**

References are made to the circular (the “**Circular**”) of Hong Kong Life Sciences and Technologies Group Limited (the “**Company**”) dated 9 August 2018, the notice of annual general meeting of the Company dated 9 August 2018 (the “**AGM Notice**”) and the form of proxy (the “**Proxy Form**”) of the Company in relation to the annual general meeting (the “**AGM**”) of the Company to be held on 7 September 2018. Unless otherwise stated, capitalized terms used in this announcement shall have the same meanings as those defined in the AGM Notice and Circular.

As mentioned in the Circular, Ms. Lam Kuo (“**Ms. Lam**”) as a non-executive Director will retire as Director by rotation and, being eligible, offer herself for re-election as Director at the AGM.

On 5 September 2018, the Company has received a written notice from Ms. Lam. Ms. Lam informed the Board that she will retire as a non-executive Director and cease to be the chairman of the Board with effect from the conclusion of the AGM due to her intention to concentrate on her own business engagement.

As a result, the Director will not propose the following ordinary resolution at the AGM in relation to the re-election of Ms. Lam (references are made to the numbering in the AGM Notice and the Proxy Form):

2. (c) to re-elect Ms. Lam Kuo as a non-executive Director

The above resolution as set out in the Circular, the AGM Notice and Proxy Form are no longer applicable and will not be put forward for consideration and approval by the Shareholders at the AGM.

The Proxy Form lodged by the Shareholders will remain valid except that no poll will be taken or counted for ordinary resolution no. 2 (c).

By order of the Board  
**Hong Kong Life Sciences and Technologies Group Limited**  
**Lu Zhiqiang**  
*Executive Director and Chief Executive Officer*

Hong Kong, 5 September 2018

*As at the date of this announcement, the Board comprises (i) five executive Directors, namely, Mr. David Lin Kao Kun, Mr. Lu Zhiqiang, Mr. Chui Kwong Kau, Ms. Li Mei and Dr. Sun Yu; (ii) one non-executive Director, namely Ms. Lam Kuo; and (iii) four independent non-executive Directors, namely Mr. Hung Yat Ming, Mr. Chan Yun Hing, Mr. Gui Qiangfang and Mr. Zhang James Jian Yuan.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the “Latest Company Announcements” page of the GEM website at <http://www.hkgem.com> for a minimum period of seven days from the date of its publication and on the Company’s website at <http://www.hklifesciences.com>.*